This page shows the latest ASH 2018 news and features for those working in and with pharma, biotech and healthcare.
new data at the ASH 2018 congress in multiple myeloma. ... Amgen also reported data at ASH on another BiTE candidate called AMG 330 which targets CD33, the same target as Regeneron’s REGN1979 which posted results in lymphoma earlier during the
Regeneron is one many companies developing bispecifics, and on Saturday at the ASH 2018 congress in San Diego, unveiled phase 1 proof of concept data for its REGN1979 in relapsed or ... Also presenting bispecific antibodies at ASH are Amgen (AMG 420) and
More from news
Approximately 0 fully matching, plus 2 partially matching documents found.
The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. ... If you would like to discuss insights from ASH 2018 or have any
Highlights in haematologic malignancy from ASH 2018. ... 2018. Communique Awards Finalist 'Healthcare Communications Leader'. 2017. Communique Awards Finalist 'Medical Education Consultancy of the Year'.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...